Krystal Biotech, Inc. Stock Split Ratio
Krystal Biotech, Inc. (KRYS) had Stock Split Ratio of 22.22% as of 2017-09-14, per its 10-Q filed 2017-11-13.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-11-05
- 2017-09-14: Stockholders' Equity Note, Stock Split, Conversion Ratio 22.22%.
- 2017-09-05: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 22.22%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|---|
| 2017-09-14 | 22.22% 10-Q · filed 2017-11-13 | |
| 2017-09-05 | 22.22% 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |